论文部分内容阅读
默克(Merck)公司开发的皮下注射用聚乙二醇化干扰素α-2b(商品名为Sylatron)于2011年4月获美国FDA批准用于淋巴结转移性黑色素瘤(node-positive melanoma)的辅助治疗。本品适应证为在确定性手术切除(包括淋巴结清扫术)后84天内显微镜活检可见淋巴结转移的黑色素瘤。
The subcutaneous injection of peginterferon alfa-2b (Sylatron), developed by Merck, was approved by the U.S. FDA in April 2011 for the aid of node-positive melanoma treatment. This product indications for definitive surgical resection (including lymph node dissection) within 84 days after microscopic biopsy lymph node metastasis of melanoma.